AEON Biopharma Inc. – Material Contracts Watch

from 8-K 2 pages Amendment to the AEON Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan

from 8-K 14 pages Employment Agreement

from 8-K 14 pages Employment Agreement

from 8-K 4 pages AEON Biopharma, Inc. Fifth Amendment to the License and Supply Agreement

from 8-K 18 pages AEON Biopharma, Inc. Amended and Restated 2023 Incentive Award Plan

from 8-K 24 pages Exchange Agreement

from 10-Q 16 pages Material contract

from 10-Q 7 pages 1 Confidential Settlement Agreement and Release This Settlement Agreement and Release (“Agreement”), Dated October 31, 2025, Is Entered Into Between Plaintiff Odeon Capital Group LLC (“Odeon” or “Plaintiff”) and Defendant AEON Biopharma, Inc. (“AEON”) (Collectively With Odeon Referred to as the “Parties”). Recitals Whereas, on September 18, 2023, Plaintiff Filed Its Complaint in the Supreme Court of New York, New York County, in the Litigation Captioned Odeon Capital Group LLC V. AEON Biopharma, Inc., Formerly Known as Priveterra Acquisition Corp., and Continental Stock Transfer & Trust Company, Bearing Index Number 654547/2023 (The “Action”); and Whereas, the Parties Desire to Avoid the Costs and Uncertainty of Further Litigation and Agree to Settle and Resolve, Completely and Finally, All Differences Between Plaintiff and AEON, as Well as Between Plaintiff and Continental Stock Transfer & Trust Company (“Continental”), and All Persons or Entities Released by This Agreement, Without Any Admission of Liability. This Includes, Without Limitation, a Desire to Resolve Completely and Finally All Claims Made and Raised by Plaintiff in the Action, Against Both AEON and Continental; and Whereas, the Parties Were Represented by Counsel Throughout the Action and During All Settlement Negotiations Which Resulted in the Settlement of the Action and Formulation of This Agreement; and Now, Therefore, in Consideration of the Sum as Outlined Below (The “Consideration”) and Other Good and Fair Consideration, the Parties Have Reached a Full and Final Compromise and Settlement of Any and All Matters in Controversy, Disputes, Causes of Action, Claims, Contentions, and Differences Between Them, and Between Plaintiff and Continental, and Hereby Agree and Understand as Follows

from 8-K 3 pages Material contract

from 8-K 16 pages Material contract

from 8-K 47 pages Material contract

from 8-K 25 pages Employment Agreement

from 8-K 51 pages Underwriting Agreement January 6, 2025

from 10-K/A 9 pages Consulting Agreement

from S-1/A 3 pages 3rd Amendment to the License and Supply Agreement

from S-1/A 5 pages ​ AEON Biopharma, Inc. ​ Second Amendment to the License and Supply Agreement ​

from S-1/A 15 pages Definitions and Construction

from 10-K 9 pages Consulting Agreement

from 8-K 4 pages ​ Polar Multi-Strategy Master Fund C/O Mourant Governance Services (Cayman) Limited 94 Solaris Avenue Camana Bay Po Box 1348 Grand Cayman Ky1-1108 Cayman Islands

from 8-K 4 pages Re: Agreement (The “Agreement”) by and Among AEON Biopharma, Inc., a Delaware Corporation (F/K/a Priveterra Acquisition Corp.), a Delaware Corporation (“Counterparty”), AEON Biopharma Sub, Inc. (F/K/a AEON Biopharma, Inc.), a Delaware Corporation (“Target”), and Acm Arrt J LLC (“Seller,” “We,” “US,” and “Our”), to Terminate the Forward Purchase Agreement Dated as of June 29, 2023 (The “Forward Purchase Agreement”) to the Above-Referenced Party